US8137683B2 - Process for the preparation of dispersions - Google Patents

Process for the preparation of dispersions Download PDF

Info

Publication number
US8137683B2
US8137683B2 US10/481,167 US48116703A US8137683B2 US 8137683 B2 US8137683 B2 US 8137683B2 US 48116703 A US48116703 A US 48116703A US 8137683 B2 US8137683 B2 US 8137683B2
Authority
US
United States
Prior art keywords
process according
solvent
dispersion
mixing chamber
aqueous phase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US10/481,167
Other versions
US20040209963A1 (en
Inventor
David Schaffner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DSM IP Assets BV
Original Assignee
DSM IP Assets BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DSM IP Assets BV filed Critical DSM IP Assets BV
Assigned to ROCHE VITAMINS INC. reassignment ROCHE VITAMINS INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SCHAFFNER, DAVID
Publication of US20040209963A1 publication Critical patent/US20040209963A1/en
Assigned to DSM IP ASSETS B.V. reassignment DSM IP ASSETS B.V. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ROCHE VITAMINS INC.
Application granted granted Critical
Publication of US8137683B2 publication Critical patent/US8137683B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F25/00—Flow mixers; Mixers for falling materials, e.g. solid particles
    • B01F25/30—Injector mixers
    • B01F25/31—Injector mixers in conduits or tubes through which the main component flows
    • B01F25/314—Injector mixers in conduits or tubes through which the main component flows wherein additional components are introduced at the circumference of the conduit
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F25/00—Flow mixers; Mixers for falling materials, e.g. solid particles
    • B01F25/40—Static mixers
    • B01F25/45—Mixers in which the materials to be mixed are pressed together through orifices or interstitial spaces, e.g. between beads
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F25/00—Flow mixers; Mixers for falling materials, e.g. solid particles
    • B01F25/40—Static mixers
    • B01F25/45—Mixers in which the materials to be mixed are pressed together through orifices or interstitial spaces, e.g. between beads
    • B01F25/452—Mixers in which the materials to be mixed are pressed together through orifices or interstitial spaces, e.g. between beads characterised by elements provided with orifices or interstitial spaces
    • B01F25/4521—Mixers in which the materials to be mixed are pressed together through orifices or interstitial spaces, e.g. between beads characterised by elements provided with orifices or interstitial spaces the components being pressed through orifices in elements, e.g. flat plates or cylinders, which obstruct the whole diameter of the tube
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F2215/00—Auxiliary or complementary information in relation with mixing
    • B01F2215/04—Technical information in relation with mixing
    • B01F2215/0413—Numerical information
    • B01F2215/0418—Geometrical information
    • B01F2215/0422—Numerical values of angles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F2215/00—Auxiliary or complementary information in relation with mixing
    • B01F2215/04—Technical information in relation with mixing
    • B01F2215/0413—Numerical information
    • B01F2215/0418—Geometrical information
    • B01F2215/0431—Numerical size values, e.g. diameter of a hole or conduit, area, volume, length, width, or ratios thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F2215/00—Auxiliary or complementary information in relation with mixing
    • B01F2215/04—Technical information in relation with mixing
    • B01F2215/0413—Numerical information
    • B01F2215/0436—Operational information
    • B01F2215/044—Numerical composition values of components or mixtures, e.g. percentage of components
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F2215/00—Auxiliary or complementary information in relation with mixing
    • B01F2215/04—Technical information in relation with mixing
    • B01F2215/0413—Numerical information
    • B01F2215/0436—Operational information
    • B01F2215/0468—Numerical pressure values
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F23/00—Mixing according to the phases to be mixed, e.g. dispersing or emulsifying
    • B01F23/04—Specific aggregation state of one or more of the phases to be mixed
    • B01F23/043—Mixing fluids or with fluids in a supercritical state, in supercritical conditions or variable density fluids

Definitions

  • the present invention relates to a process for the preparations of aqueous dispersions. More particularly, the present invention relates to a process for the preparation of a dispersion of an active substance or composition in an aqueous phase.
  • aqueous dispersions of an active substance or composition are prepared by a process which comprises dispersing in an aqueous phase a solution of such substance or composition in dimethylether or in a C 4 -hydrocarbon or mixtures thereof in super- or nearcritical state, decompressing the mixture and separating the dispersion from gaseous solvent.
  • dispersion as used herein encompasses emulsions and suspensions and refers to systems wherein the dispersed particles are in the micro or nano size range and, preferably, have a mean particle diameter of about 50 to about 300 nm.
  • active substance or composition denotes any substance or composition which is soluble in dimethylether or C 4 -hydrocarbons and substantially water-insoluble and which may be solid or liquid under ambient conditions and which usually exerts a physiological activity.
  • Such active substances are especially the fat-soluble vitamins A, D, E, K; and the carotenoids like ⁇ -carotene, canthaxanthin, apocarotenal, astaxanthin, apoester, lutein, lycopene, zeaxanthin, citranaxanthin, torularhodin; fat-soluble pharmaceuticals; other fat-soluble (health care) ingredients like PUFA (polyunsaturated fatty acids), curcumin, coenzyme Q10, ⁇ -lipoic acid.
  • PUFA polyunsaturated fatty acids
  • C 4 -hydrocarbons are hydrocarbons having four carbon atoms which can be saturated such as n-butane and isobutane, or unsaturated such as 1-butene, trans-butene and isobutene.
  • trans-butene, 1-butene and dimethylether, especially 1-butene are preferred, particularly for the preparation of aqueous ⁇ -carotene dispersions.
  • the process of the present invention is suitably carried out by individually feeding an aqueous phase and a solution of an active substance or composition in the appropriate solvent in super- or nearcritical state into a mixing chamber and decompressing the mixture.
  • the process of this invention can be carried out as depicted in FIG. 1 .
  • the active substance or composition is dispersed in an appropriate pressurized solvent, e.g., dimethylether, in an autoclave 1 .
  • the pressure of the solvent in autoclave 1 should be above the saturation vapor pressure.
  • the dispersion obtained is fed by means of a high pressure pump 2 (e.g., a diaphragm pump Lewa Typ EL-3; supplier: HERBERT OTT AG, Missionsstrasse 22 , CH-4003 Basel) into a mixing chamber 4 via a heat exchanger (e.g., a double-pipe heat exchanger) 3 in such a manner that temperature and pressure are close to or exceed the critical constants of the solvent, i.e., the solvent reaches the super- or nearcritical state.
  • the pressure is about 45 bar to about 2000 bar, conveniently about 45 bar to about 300 bar, and preferably about 80 bar to about 200 bar.
  • aqueous phase which may contain additional agents such as stabilizers or surfactants is fed through a high pressure pump 6 (e.g., a piston pump LABOMATIC HD-300; supplier: LABOMATIC Instruments AG, Ringstr.13, CH-4123 Allschwil) and a heat exchanger (e.g., a double-pipe heat exchanger) 7 to the mixing chamber 4 at a pressure substantially corresponding to that build up by pumps 2 and 6 and at a temperature sufficient to maintain super- or nearcritical conditions in the mixing chamber 4 .
  • a high pressure pump 6 e.g., a piston pump LABOMATIC HD-300; supplier: LABOMATIC Instruments AG, Ringstr.13, CH-4123 Allschwil
  • a heat exchanger e.g., a double-pipe heat exchanger
  • the pumps 2 and 6 may be any pump conventionally used in high-pressure technology such as diaphragm or piston pumps.
  • heat-exchangers 3 and 7 conventional heat exchangers such as tubular or double-pipe exchangers may be used.
  • the autoclaves 1 and 5 e.g., METIMEX Typ HPM, supplier: PREMEX REACTOR AG, Industriestrasse 11 , Postfach 444 ) are suitably designed to permit pre-heating of their contents.
  • the mixing chamber 4 comprises at least one inlet for the aqueous phase, at least one inlet for the non-aqueous (solvent) phase, and an outlet comprising an expansion aperture.
  • the inlets for the aqueous phase and the solvent phase maybe arranged at an angle of between 0 degree and 180 degree, i.e., parallel or opposite to each other, or in such a manner that the two streams meet at an angle different from 0 degree and 180 degree, e.g., at an angle of about 30 to 90 degree.
  • the mixing chamber is suitably tubular and has a dimension to secure turbulent conditions, i.e., is sufficiently small.
  • the aperture 8 suitably is circular and suitably has a diameter of about 0.05 mm to about 1.0 mm and preferably about 0.1 mm to 0.4 mm.
  • FIG. 2 shows an exemplary expansion unit consisting of mixing chamber 4 and expansion aperture 8 .
  • a pre-emulsion i.e., an emulsion wherein the particle size is above the ultimately desired size
  • the aperture 8 By passing the aperture 8 , the emulsion will be expanded.
  • the compressed solvent By the expansion the compressed solvent will be evaporated and simultaneously the particles will be precipitated.
  • the final dispersion exits ( 12 ) the unit and can be easily separated from the gaseous solvent.
  • temperature and pressure will have to be adjusted to the particular solvent used in the process of the present invention to make sure that the system achieves the hypercritical state.
  • the temperature of the fed streams to the mixing chamber will have to be at least 80° C.
  • the temperature is adjusted to a temperature of 80 to 160° C.
  • the residence time of the solution of the active substance in the heat exchanger is not narrowly critical and generally is within the range of seconds.
  • the residence time of the solution of the mixture in the mixing chamber is also not narrowly critical but is preferably no more than about 0.01 to about 0.1 seconds.
  • the ratio between the active substance or composition and the solvent is not narrowly critical and depends on the particular choice of the components involved. As will be readily apparent, the amount of solvent must be such to secure complete dissolution of the active substance or composition in the supercritical solvent.
  • the ratio between the aqueous phase and the solvent phase) i.e., the ratio between the fed stream of aqueous phase and the hypercritical solvent which contains the active substance or-composition is also not narrowly critical.
  • the upper limit of the concentration of active substance or composition in the final dispersion than can be prepared by the process of the invention ultimately depends on the solubility of the active substance or composition in the solvent. Dispersions containing up to about 50% by weight may be prepared. Suitably, the process conditions are adjusted in such a manner that the final dispersion contains about 0.1 to 20% by weight of active substance or composition, e.g., about 10% by weight.
  • the aqueous phase may contain additional ingredients, such as carriers, e.g. bovine, swine or fish gelatin, gum acacia, modified food starches, cellulose derivatives, pectins, ligninsulfonates; surfactants, e.g. sugar esters, polyglycerol fatty acid esters, Tween; stabilizers or antioxidants, e.g. sodium ascorbate, ascorbyl palmitate, dl- ⁇ -tocopherol, mixed tocopherols, BHT, BHA, or EMQ.
  • carriers e.g. bovine, swine or fish gelatin, gum acacia, modified food starches, cellulose derivatives, pectins, ligninsulfonates
  • surfactants e.g. sugar esters, polyglycerol fatty acid esters, Tween
  • stabilizers or antioxidants e.g. sodium ascorbate, ascorbyl palmitate, dl- ⁇ -to
  • the dispersion or emulsion obtained can be further converted into a solid powder by means know per se, e.g. spray-drying or in a fluidized bed.
  • the emulsions or dispersions provided by the present invention can find use for all purposes were finely dispersed forms of substantially water-insoluble and fat-soluble substances or compositions are required, e.g., for coloring foodstuff or animal feed with carotenoids.
  • Autoclave 1 was charged with 50 g of ⁇ -carotene, 6 g of ⁇ -tocopherol, 22.9 g of corn oil and 740 g of dimethylether.
  • the oily phase in autoclave 1 (pre-heated to 30° C./30 bar N 2 ) was passed to heat-exchanger 3 by diaphragm pump 2 (Lewa Typ EL 3) under a pressure of 150 bar where it was heated to 155° C. within a residence time of 5-10 sec.
  • Aqueous phase and oily phase were simultaneously passed through mixing chamber 4 and aperture 8 having an orifice diameter of 0.25 mm to residence zone 9 where the mixture was decompressed to atmospheric pressure, producing about 5-6 kg per hour of aqueous, solvent-free dispersion of ⁇ -carotene in a gelatin/sugar matrix.
  • the mean particle size of the dispersion was 117 nm (variance 20 nm).
  • Example 2 An installation as described in Example 1 was used.
  • a 2 liter stainless steel autoclave 5 was charged with 1100 g of water, 80 g ascorbyl palmitate, 258 g of fish gelatin and 550 g of sugar.
  • the aqueous phase in autoclave 5 (pre-heated to 60° C./6 bar N 2 ) was passed to heat exchanger 7 by piston pump 6 at a flow rate of 120 g/min under a pressure of 149 bar where it was heated to 64° C. within a residence time of 6-12 sec.
  • Autoclave 1 was charged with 50 g of ⁇ -carotene, 6 g of ⁇ -tocopherol, 22.9 g of corn oil and 570 g of 1-butene.
  • the oily phase in autoclave 1 (pre-heated to 30° C./30 bar N 2 ) was passed to heat-exchanger 3 by diaphragm pump 2 under a pressure of 149 bar where it was heated to 127° C. within a residence time of 5-10 sec.
  • Aqueous phase and oily phase were simultaneously passed through mixing chamber 4 and aperture 8 having an orifice diameter of 0.25 mm to residence zone 9 where the mixture was decompressed to atmospheric pressure, producing about 7-8 kg per hour of aqueous, solvent-free dispersion of ⁇ -carotene in a gelatin/sugar matrix.
  • the mean particle size of the dispersion was 223 nm (variance 87 nm).
  • Example 2 An installation as described in Example 1 was used.
  • a 2 liter stainless steel autoclave 5 was charged with 1100 g of water, 80 g of ascorbyl palmitate, 258 g of fish gelatin and 550 g of sugar.
  • the aqueous phase in autoclave 5 (pre-heated to 60° C./ 6 bar N 2 ) was passed to heat exchanger 7 by piston pump 6 at a flow rate of 115 g/min under a pressure of 148 bar where it was heated to 63.7° C. within a residence time of 6-12 sec.
  • Autoclave 1 was charged with 100 g of ⁇ -carotene, 12.5 g of ⁇ -tocopherol, 45.9 g of corn oil and 590 g of trans-butene.
  • the oily phase in autoclave 1 (pre-heated to 30° C./30 bar N 2 ) was passed to heat-exchanger 3 by diaphragm pump 2 under a pressure of 148 bar where it was heated to 137° C. within a residence time of 5-10 sec.
  • Aqueous phase and oily phase were simultaneously passed through mixing chamber 4 and aperture 8 having an orifice diameter of 0.2 mm to residence zone 9 where the mixture was decompressed to atmospheric pressure, producing about 6-7 kg per hour of aqueous, solvent-free dispersion of ⁇ -carotene in a gelatin/sugar matrix.
  • the produced mean particle size of the dispersion was 223 nm (variance 73 nm).
  • Example 2 An installation as described in Example 1 was used.
  • a 2 liter stainless steel autoclave 5 was charged with 130 g of water, 62 g of ascorbyl palmitate, 242 g of fish gelatin and 384 g of sugar.
  • the aqueous phase in autoclave 5 (pre-heated to 60° C./6 bar N 2 ) was passed to heat exchanger Z by piston pump 6 at a flow rate of 60 g/min under a pressure of 109 bar where it was heated to 75.8° C. within a residence time of 6-12 sec.
  • Autoclave 1 was charged with 25 g of lycopene, 3.1 g of ⁇ -tocopherol, 11.5 g of corn oil and 740 g of dimethylether.
  • the oily phase in autoclave 1 (pre-heated to 30° C./30 bar N 2 ) was passed to heat-exchanger 3 by diaphragm pump 2 under a pressure of 109 bar where it was heated to 137° C. within a residence time of 5-10 sec.
  • Aqueous phase and oily phase were simultaneously passed through mixing chamber 4 and aperture 8 having an orifice diameter of 0.25 mm to residence zone 9 where the mixture was decompressed to atmospheric pressure, producing about 3-4 kg of aqueous, solvent-free dispersion of lycopene in a gelatin/sugar matrix per hour.
  • the produced mean particle size of the dispersion was 171 nm (variance 60 nm).
  • Example. 1 An installation as described in Example. 1 was used.
  • a 2 liter stainless steel autoclave 5 was charged with 330 g of water, 68 g of ascorbyl palmitate, 188 g of lecithin and 1412 g of lebboline.
  • the aqueous phase in autoclave 5 (pre-heated to 60° C./ 6 bar N 2 ) was passed to heat exchanger 7 by piston pump 6 at a flow rate of 120 g/min under a pressure of 192 bar where it was heated to 67° C. within a residence time of 6-12 sec.
  • Autoclave 1 was charged with 50 g of ⁇ -carotene, 9.4 g of ⁇ -tocopherol, 34.4 g of corn oil and 740 g of dimethylether.
  • the oily phase in autoclave 1 (pre-heated to 30° C./30 bar N 2 ) was passed to heat-exchanger 3 by diaphragm pump 2 under a pressure of 192 bar where it was heated to 170° C. within a residence time of 5-10 sec.
  • Aqueous phase and oily phase were simultaneously passed through mixing chamber 4 and aperture 8 having an orifice diameter of 0.2 mm to residence zone 9 where the mixture was decompressed to atmospheric pressure, producing about 7-8 kg per hour of aqueous, solvent-free dispersion of ⁇ -carotene in a lecithin/lebboline matrix.
  • the mean particle size of the dispersion was 174 nm (variance 36 nm).

Abstract

The present invention relates to a process of a dispersion of an active substance or composition in a aqueous phase which comprises dispersing in an aqueous phase a solution of such substance or composition in dimethylether or in a C4-hydrocarbon or mixtures thereof in super- or nearcritical state, decompressing the mixture and separating the dispersion from the gaseous solvent.

Description

This application is the National Stage of International Application No. PCT/EP02/06328, filed Jun. 10, 2002.
The present invention relates to a process for the preparations of aqueous dispersions. More particularly, the present invention relates to a process for the preparation of a dispersion of an active substance or composition in an aqueous phase. In accordance with the present invention, aqueous dispersions of an active substance or composition are prepared by a process which comprises dispersing in an aqueous phase a solution of such substance or composition in dimethylether or in a C4-hydrocarbon or mixtures thereof in super- or nearcritical state, decompressing the mixture and separating the dispersion from gaseous solvent.
The term “dispersion” as used herein encompasses emulsions and suspensions and refers to systems wherein the dispersed particles are in the micro or nano size range and, preferably, have a mean particle diameter of about 50 to about 300 nm. The term “active substance or composition” denotes any substance or composition which is soluble in dimethylether or C4-hydrocarbons and substantially water-insoluble and which may be solid or liquid under ambient conditions and which usually exerts a physiological activity. Examples of such active substances are especially the fat-soluble vitamins A, D, E, K; and the carotenoids like β-carotene, canthaxanthin, apocarotenal, astaxanthin, apoester, lutein, lycopene, zeaxanthin, citranaxanthin, torularhodin; fat-soluble pharmaceuticals; other fat-soluble (health care) ingredients like PUFA (polyunsaturated fatty acids), curcumin, coenzyme Q10, α-lipoic acid.
Examples of C4-hydrocarbons are hydrocarbons having four carbon atoms which can be saturated such as n-butane and isobutane, or unsaturated such as 1-butene, trans-butene and isobutene. Of these, trans-butene, 1-butene and dimethylether, especially 1-butene, are preferred, particularly for the preparation of aqueous β-carotene dispersions.
The process of the present invention is suitably carried out by individually feeding an aqueous phase and a solution of an active substance or composition in the appropriate solvent in super- or nearcritical state into a mixing chamber and decompressing the mixture. Schematically, the process of this invention can be carried out as depicted in FIG. 1. The active substance or composition is dispersed in an appropriate pressurized solvent, e.g., dimethylether, in an autoclave 1. The pressure of the solvent in autoclave 1 should be above the saturation vapor pressure. The dispersion obtained is fed by means of a high pressure pump 2 (e.g., a diaphragm pump Lewa Typ EL-3; supplier: HERBERT OTT AG, Missionsstrasse 22, CH-4003 Basel) into a mixing chamber 4 via a heat exchanger (e.g., a double-pipe heat exchanger) 3 in such a manner that temperature and pressure are close to or exceed the critical constants of the solvent, i.e., the solvent reaches the super- or nearcritical state. For instance, the pressure is about 45 bar to about 2000 bar, conveniently about 45 bar to about 300 bar, and preferably about 80 bar to about 200 bar. In a second autoclave 5 the aqueous phase which may contain additional agents such as stabilizers or surfactants is fed through a high pressure pump 6 (e.g., a piston pump LABOMATIC HD-300; supplier: LABOMATIC Instruments AG, Ringstr.13, CH-4123 Allschwil) and a heat exchanger (e.g., a double-pipe heat exchanger) 7 to the mixing chamber 4 at a pressure substantially corresponding to that build up by pumps 2 and 6 and at a temperature sufficient to maintain super- or nearcritical conditions in the mixing chamber 4. In the mixing chamber 4 the phases are mixed and decompressed through an aperture 8, then pass a residence zone 9 thus producing a finely dispersed aqueous, solvent-free suspension or emulsion.
The pumps 2 and 6 may be any pump conventionally used in high-pressure technology such as diaphragm or piston pumps. For the heat- exchangers 3 and 7 conventional heat exchangers such as tubular or double-pipe exchangers may be used. The autoclaves 1 and 5 (e.g., METIMEX Typ HPM, supplier: PREMEX REACTOR AG, Industriestrasse 11, Postfach 444) are suitably designed to permit pre-heating of their contents. The mixing chamber 4 comprises at least one inlet for the aqueous phase, at least one inlet for the non-aqueous (solvent) phase, and an outlet comprising an expansion aperture. The inlets for the aqueous phase and the solvent phase maybe arranged at an angle of between 0 degree and 180 degree, i.e., parallel or opposite to each other, or in such a manner that the two streams meet at an angle different from 0 degree and 180 degree, e.g., at an angle of about 30 to 90 degree. The mixing chamber is suitably tubular and has a dimension to secure turbulent conditions, i.e., is sufficiently small.
The aperture 8 suitably is circular and suitably has a diameter of about 0.05 mm to about 1.0 mm and preferably about 0.1 mm to 0.4 mm. By passing the aperture the dispersion will be expanded. By the expansion the compressed solvent will be evaporated and simultaneously the particle will be precipitated. After the residence time in the pipe the final dispersion can be easily separated from the gaseous solvent.
FIG. 2 shows an exemplary expansion unit consisting of mixing chamber 4 and expansion aperture 8. By mixing of the solvent phase 10 with the aqueous phase 11 in the mixing chamber a pre-emulsion (i.e., an emulsion wherein the particle size is above the ultimately desired size) results. By passing the aperture 8, the emulsion will be expanded. By the expansion the compressed solvent will be evaporated and simultaneously the particles will be precipitated. After the residence time in the residence zone 9 the final dispersion exits (12) the unit and can be easily separated from the gaseous solvent.
As will be readily understood, temperature and pressure will have to be adjusted to the particular solvent used in the process of the present invention to make sure that the system achieves the hypercritical state. Thus, when using dimethylether which has the critical constants Tk 126.9° C. and pk 53.7 bar, the temperature of the fed streams to the mixing chamber will have to be at least 80° C. Preferably, when using dimethylether, the temperature is adjusted to a temperature of 80 to 160° C. The residence time of the solution of the active substance in the heat exchanger is not narrowly critical and generally is within the range of seconds. The residence time of the solution of the mixture in the mixing chamber is also not narrowly critical but is preferably no more than about 0.01 to about 0.1 seconds.
The ratio between the active substance or composition and the solvent is not narrowly critical and depends on the particular choice of the components involved. As will be readily apparent, the amount of solvent must be such to secure complete dissolution of the active substance or composition in the supercritical solvent. The ratio between the aqueous phase and the solvent phase) i.e., the ratio between the fed stream of aqueous phase and the hypercritical solvent which contains the active substance or-composition is also not narrowly critical. The upper limit of the concentration of active substance or composition in the final dispersion than can be prepared by the process of the invention ultimately depends on the solubility of the active substance or composition in the solvent. Dispersions containing up to about 50% by weight may be prepared. Suitably, the process conditions are adjusted in such a manner that the final dispersion contains about 0.1 to 20% by weight of active substance or composition, e.g., about 10% by weight.
The aqueous phase, and to some extent also the solvent phase, may contain additional ingredients, such as carriers, e.g. bovine, swine or fish gelatin, gum acacia, modified food starches, cellulose derivatives, pectins, ligninsulfonates; surfactants, e.g. sugar esters, polyglycerol fatty acid esters, Tween; stabilizers or antioxidants, e.g. sodium ascorbate, ascorbyl palmitate, dl-α-tocopherol, mixed tocopherols, BHT, BHA, or EMQ.
The dispersion or emulsion obtained can be further converted into a solid powder by means know per se, e.g. spray-drying or in a fluidized bed.
The emulsions or dispersions provided by the present invention can find use for all purposes were finely dispersed forms of substantially water-insoluble and fat-soluble substances or compositions are required, e.g., for coloring foodstuff or animal feed with carotenoids.
The invention is further illustrated by the following Examples.
EXAMPLE 1
In this Example, an installation as depicted schematically in FIG. 1 was used. A 2 liter stainless steel autoclave 5 was charged with 1100 g of water, 80 g of ascorbyl palmitate, 258 g of fish gelatin and 550 g of sugar. The aqueous phase in autoclave 5 (pre-heated to 60° C./ 6 bar N2) was passed to heat exchanger 7 by piston pump 6 (LABOMATIC HD 300) at a flow rate of 90 g/min under a pressure of 150 bar where it was heated to 68.5° C. within a residence time of 6-12 sec. Autoclave 1 was charged with 50 g of β-carotene, 6 g of α-tocopherol, 22.9 g of corn oil and 740 g of dimethylether. The oily phase in autoclave 1 (pre-heated to 30° C./30 bar N2) was passed to heat-exchanger 3 by diaphragm pump 2 (Lewa Typ EL 3) under a pressure of 150 bar where it was heated to 155° C. within a residence time of 5-10 sec. Aqueous phase and oily phase were simultaneously passed through mixing chamber 4 and aperture 8 having an orifice diameter of 0.25 mm to residence zone 9 where the mixture was decompressed to atmospheric pressure, producing about 5-6 kg per hour of aqueous, solvent-free dispersion of β-carotene in a gelatin/sugar matrix. The mean particle size of the dispersion was 117 nm (variance 20 nm).
EXAMPLE 2
In this Example, an installation as described in Example 1 was used. A 2 liter stainless steel autoclave 5 was charged with 1100 g of water, 80 g ascorbyl palmitate, 258 g of fish gelatin and 550 g of sugar. The aqueous phase in autoclave 5 (pre-heated to 60° C./6 bar N2) was passed to heat exchanger 7 by piston pump 6 at a flow rate of 120 g/min under a pressure of 149 bar where it was heated to 64° C. within a residence time of 6-12 sec. Autoclave 1 was charged with 50 g of β-carotene, 6 g of α-tocopherol, 22.9 g of corn oil and 570 g of 1-butene. The oily phase in autoclave 1 (pre-heated to 30° C./30 bar N2) was passed to heat-exchanger 3 by diaphragm pump 2 under a pressure of 149 bar where it was heated to 127° C. within a residence time of 5-10 sec. Aqueous phase and oily phase were simultaneously passed through mixing chamber 4 and aperture 8 having an orifice diameter of 0.25 mm to residence zone 9 where the mixture was decompressed to atmospheric pressure, producing about 7-8 kg per hour of aqueous, solvent-free dispersion of β-carotene in a gelatin/sugar matrix. The mean particle size of the dispersion was 223 nm (variance 87 nm).
EXAMPLE 3
In this Example, an installation as described in Example 1 was used. A 2 liter stainless steel autoclave 5 was charged with 1100 g of water, 80 g of ascorbyl palmitate, 258 g of fish gelatin and 550 g of sugar. The aqueous phase in autoclave 5 (pre-heated to 60° C./ 6 bar N2) was passed to heat exchanger 7 by piston pump 6 at a flow rate of 115 g/min under a pressure of 148 bar where it was heated to 63.7° C. within a residence time of 6-12 sec. Autoclave 1 was charged with 100 g of β-carotene, 12.5 g of α-tocopherol, 45.9 g of corn oil and 590 g of trans-butene. The oily phase in autoclave 1 (pre-heated to 30° C./30 bar N2) was passed to heat-exchanger 3 by diaphragm pump 2 under a pressure of 148 bar where it was heated to 137° C. within a residence time of 5-10 sec. Aqueous phase and oily phase were simultaneously passed through mixing chamber 4 and aperture 8 having an orifice diameter of 0.2 mm to residence zone 9 where the mixture was decompressed to atmospheric pressure, producing about 6-7 kg per hour of aqueous, solvent-free dispersion of β-carotene in a gelatin/sugar matrix. The produced mean particle size of the dispersion was 223 nm (variance 73 nm).
EXAMPLE 4
In this Example, an installation as described in Example 1 was used. A 2 liter stainless steel autoclave 5 was charged with 130 g of water, 62 g of ascorbyl palmitate, 242 g of fish gelatin and 384 g of sugar. The aqueous phase in autoclave 5 (pre-heated to 60° C./6 bar N2) was passed to heat exchanger Z by piston pump 6 at a flow rate of 60 g/min under a pressure of 109 bar where it was heated to 75.8° C. within a residence time of 6-12 sec. Autoclave 1 was charged with 25 g of lycopene, 3.1 g of α-tocopherol, 11.5 g of corn oil and 740 g of dimethylether. The oily phase in autoclave 1 (pre-heated to 30° C./30 bar N2) was passed to heat-exchanger 3 by diaphragm pump 2 under a pressure of 109 bar where it was heated to 137° C. within a residence time of 5-10 sec. Aqueous phase and oily phase were simultaneously passed through mixing chamber 4 and aperture 8 having an orifice diameter of 0.25 mm to residence zone 9 where the mixture was decompressed to atmospheric pressure, producing about 3-4 kg of aqueous, solvent-free dispersion of lycopene in a gelatin/sugar matrix per hour. The produced mean particle size of the dispersion was 171 nm (variance 60 nm).
EXAMPLE 5
In this Example, an installation as described in Example. 1 was used. A 2 liter stainless steel autoclave 5 was charged with 330 g of water, 68 g of ascorbyl palmitate, 188 g of lecithin and 1412 g of lebboline. The aqueous phase in autoclave 5 (pre-heated to 60° C./ 6 bar N2) was passed to heat exchanger 7 by piston pump 6 at a flow rate of 120 g/min under a pressure of 192 bar where it was heated to 67° C. within a residence time of 6-12 sec. Autoclave 1 was charged with 50 g of β-carotene, 9.4 g of α-tocopherol, 34.4 g of corn oil and 740 g of dimethylether. The oily phase in autoclave 1 (pre-heated to 30° C./30 bar N2) was passed to heat-exchanger 3 by diaphragm pump 2 under a pressure of 192 bar where it was heated to 170° C. within a residence time of 5-10 sec. Aqueous phase and oily phase were simultaneously passed through mixing chamber 4 and aperture 8 having an orifice diameter of 0.2 mm to residence zone 9 where the mixture was decompressed to atmospheric pressure, producing about 7-8 kg per hour of aqueous, solvent-free dispersion of β-carotene in a lecithin/lebboline matrix. The mean particle size of the dispersion was 174 nm (variance 36 nm).

Claims (18)

The invention claimed is:
1. A process for the preparation of a dispersion which comprises feeding an aqueous phase and a solvent phase which comprises a solution of an active substance or composition selected from the group consisting of a fat-soluble vitamin, a pharmaceutical, a carotenoid, and a polyunsaturated fatty acid in dimethylether or in a C4-hydrocarbon or mixtures thereof into a mixing chamber, wherein at least one of the solution or the aqueous phase comprises a carrier, decompressing the mixture and separating the dispersion from gaseous solvent, wherein
(a) the active substance or composition is dispersed in dimethylether or in a C4-hydrocarbon or mixtures thereof, heated in a heat exchanger for about 5 to 10 seconds, and fed into the mixing chamber by a high pressure pump in such a manner that temperature and pressure are close to or exceed the critical constants of the solvent;
(b) the aqueous phase comprises a carrier selected from the group consisting of bovine gelatin, swine gelatin, fish gelatin, gum acacia, modified food starches, cellulose derivatives, pectins, and ligninsulfonates, and is fed into the mixing chamber at a pressure and temperature sufficient to maintain super- or nearcritical conditions;
(c) the said two phases are mixed in the mixing chamber under turbulent conditions to produce a pre-emulsion; and
(d) the pre-emulsion is decompressed through an aperture, which has a diameter of 0.05 mm to about 1.0 mm and then passes through a residence zone to produce the dispersion which is a finely-dispersed aqueous, solvent-free suspension or emulsion.
2. A process according to claim 1 wherein the active substance or composition is a carotenoid.
3. A process according to claim 2 wherein the carotenoid is β-carotene.
4. A process according to claim 1 wherein the solvent is selected from the group consisting of dimethylether, 1-butene, and transbutene.
5. A process according claim 1 wherein the dispersion has dispersed particles which have a mean diameter of from about 20 to about 300 nm.
6. A process according to claim 2 wherein the solvent is selected from the group consisting of dimethylether, 1-butene, and transbutene.
7. A process according to claim 3 wherein the solvent is selected from the group consisting of dimethylether, 1-butene, and transbutene.
8. A process according claim 2 wherein the dispersion has dispersed particles which have a mean diameter of from about 20 to about 300 nm.
9. A process according claim 3 wherein the dispersion has dispersed particles which have a mean diameter of from about 20 to about 300 nm.
10. A process according claim 4 wherein the dispersion has dispersed particles which have a mean diameter of from about 20 to about 300 nm.
11. A process according to claim 1 wherein the solvent phase comprises a carrier selected from the group consisting of bovine gelatin, swine gelatin, fish gelatin, gum acacia, modified food starches, cellulose derivatives, pectins, and ligninsulfonates.
12. A process according to claim 1 wherein at least one of the solution or the aqueous phase further comprises a surfactant, a stabilizer, or an antioxidant.
13. A process according to claim 1, wherein the solution of an active substance or composition in dimethylether or in a C4-hydrocarbon or mixtures thereof is fed into the mixing chamber by operation of a high pressure pump and via a heat exchanger.
14. A process according to claim 1, wherein the aqueous phase is fed through a high pressure pump and a heat exchanger to the mixing chamber.
15. The process according to claim 1, wherein the two phases are in the mixing chamber for no more than about 0.01 to about 0.1 seconds.
16. The process according to claim 1, wherein the aqueous phase is heated in a heat exchanger and fed by a high pressure pump into the mixing chamber.
17. The process according to claim 1, wherein said temperature and pressure at step (a) are at least 80° C. and about 45 bar to about 2000 bar, respectively, and said pressure at step (b) is about 45 bar to about 2000 bar.
18. The process according to claim 17, wherein said pressure at step (b) substantially corresponds to said pressure at step (a).
US10/481,167 2001-06-19 2002-06-10 Process for the preparation of dispersions Active 2025-07-09 US8137683B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP01114619 2001-06-19
EP011146198 2001-06-19
EP01114619 2001-06-19
PCT/EP2002/006328 WO2002102298A2 (en) 2001-06-19 2002-06-10 Process for the preparation of dispersions

Publications (2)

Publication Number Publication Date
US20040209963A1 US20040209963A1 (en) 2004-10-21
US8137683B2 true US8137683B2 (en) 2012-03-20

Family

ID=8177743

Family Applications (1)

Application Number Title Priority Date Filing Date
US10/481,167 Active 2025-07-09 US8137683B2 (en) 2001-06-19 2002-06-10 Process for the preparation of dispersions

Country Status (10)

Country Link
US (1) US8137683B2 (en)
EP (1) EP1399136B1 (en)
JP (1) JP4630545B2 (en)
KR (1) KR100891601B1 (en)
CN (1) CN100366243C (en)
AT (1) ATE291905T1 (en)
CA (1) CA2448993A1 (en)
DE (1) DE60203501T2 (en)
ES (1) ES2238588T3 (en)
WO (1) WO2002102298A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10463061B2 (en) 2004-11-19 2019-11-05 Dsm Ip Assets B.V. Modified plant gums for preparations of active ingredients
AU2006235643B2 (en) * 2005-04-11 2010-12-16 New Cell Formulations Ltd. Supplemental dietary composition for increasing muscle size and strength
EP2210593A3 (en) 2009-01-21 2011-05-18 DSM IP Assets B.V. Tablettable formulations of vitamin A and derivatives thereof
EP2992950A1 (en) * 2014-09-03 2016-03-09 The Procter and Gamble Company Method for producing aqueous emulsions or suspensions
CN110115952B (en) * 2018-02-05 2021-10-15 绍兴吉能纳米科技有限公司 High-pressure homogenizing method capable of using low-temperature liquefied gas
JP2022551231A (en) * 2019-10-11 2022-12-08 ディーエスエム アイピー アセッツ ビー．ブイ． A new feed additive for fat-soluble vitamins
WO2022078924A1 (en) * 2020-10-12 2022-04-21 Dsm Ip Assets B.V. New feed additives of fat-soluble vitamins

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3625863A (en) * 1968-10-05 1971-12-07 Bayer Ag Process for the production of fixed bed oxidation catalysts
DE2943267A1 (en) 1979-10-26 1981-05-07 Basf Ag, 6700 Ludwigshafen Finely dispersed carotenoid pigments prodn. - by dissolving carotenoid in a supercritical gas, pref. carbon di:oxide, and dispersing the soln. in an aq. colloidal matrix
EP0065193A2 (en) 1981-05-15 1982-11-24 BASF Aktiengesellschaft Process for the manufacture of powdery, finely divided preparations of carotenoids or retinoids
EP0239949A2 (en) 1986-04-04 1987-10-07 BASF Aktiengesellschaft Process for the manufacture of powdery finely divided preparations of carotenoids
EP0677332A2 (en) 1994-04-08 1995-10-18 Sievers, Robert, E. Methods and apparatus for fine particle formation
WO1997031691A1 (en) 1996-03-01 1997-09-04 The University Of Kansas Methods and apparatus for particle precipitation and coating using near-critical and supercritical antisolvents
WO1998016204A1 (en) * 1996-10-14 1998-04-23 F. Hoffmann-La Roche Ag Process for the manufacture of a pulverous preparation
WO1999052504A1 (en) 1998-04-09 1999-10-21 F. Hoffmann-La Roche Ag Process for the manufacture of (sub)micron sized particles by dissolving in compressed gas and surfactants
WO2000015329A1 (en) 1998-09-15 2000-03-23 Henkel Kommanditgesellschaft Auf Aktien Method for producing nanoparticles
DE19904990A1 (en) 1998-10-21 2000-04-27 Fraunhofer Ges Forschung Superfine powdered materials, used in pharmaceuticals, produced by injection of very low viscosity liquid colloidal suspensions into supercritical gas

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59306812D1 (en) * 1992-04-14 1997-07-31 Hoffmann La Roche Preparations of fat-soluble substances
DE4445341A1 (en) * 1994-12-19 1996-06-20 Basf Ag Method and device for producing dispersions containing active ingredients

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3625863A (en) * 1968-10-05 1971-12-07 Bayer Ag Process for the production of fixed bed oxidation catalysts
DE2943267A1 (en) 1979-10-26 1981-05-07 Basf Ag, 6700 Ludwigshafen Finely dispersed carotenoid pigments prodn. - by dissolving carotenoid in a supercritical gas, pref. carbon di:oxide, and dispersing the soln. in an aq. colloidal matrix
EP0065193A2 (en) 1981-05-15 1982-11-24 BASF Aktiengesellschaft Process for the manufacture of powdery, finely divided preparations of carotenoids or retinoids
US4522743A (en) 1981-05-15 1985-06-11 Basf Aktiengesellschaft Preparation of finely divided pulverulent carotinoid and retinoid compositions
EP0239949A2 (en) 1986-04-04 1987-10-07 BASF Aktiengesellschaft Process for the manufacture of powdery finely divided preparations of carotenoids
US4726955A (en) * 1986-04-04 1988-02-23 Basf Aktiengesellschaft Preparation of finely divided, pulverulent carotenoid preparations
US5639441A (en) * 1992-03-06 1997-06-17 Board Of Regents Of University Of Colorado Methods for fine particle formation
EP0677332A2 (en) 1994-04-08 1995-10-18 Sievers, Robert, E. Methods and apparatus for fine particle formation
WO1997031691A1 (en) 1996-03-01 1997-09-04 The University Of Kansas Methods and apparatus for particle precipitation and coating using near-critical and supercritical antisolvents
WO1998016204A1 (en) * 1996-10-14 1998-04-23 F. Hoffmann-La Roche Ag Process for the manufacture of a pulverous preparation
EP1097705A2 (en) 1996-10-14 2001-05-09 F. Hoffmann-La Roche Ag Process for the manufacture of a pulverous preparation
WO1999052504A1 (en) 1998-04-09 1999-10-21 F. Hoffmann-La Roche Ag Process for the manufacture of (sub)micron sized particles by dissolving in compressed gas and surfactants
WO2000015329A1 (en) 1998-09-15 2000-03-23 Henkel Kommanditgesellschaft Auf Aktien Method for producing nanoparticles
DE19904990A1 (en) 1998-10-21 2000-04-27 Fraunhofer Ges Forschung Superfine powdered materials, used in pharmaceuticals, produced by injection of very low viscosity liquid colloidal suspensions into supercritical gas

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Berger, T., "Mit verdichteten Gasen kristallisieren", Gas Aktuell, vol. 52, pp. 21-25.
Bungert, B., et al., "Innovative Verfahren mit komprimierten Gasen", Chemie Inbenieur Technik, vol. 69, pp. 298-311 (1997).
Derwent English abstract of DE 199 04 990, Apr. 27, 2000.
Derwent English abstract of DE 29 43 267, May 7, 1981.

Also Published As

Publication number Publication date
JP2004529206A (en) 2004-09-24
EP1399136B1 (en) 2005-03-30
CN100366243C (en) 2008-02-06
KR20040012865A (en) 2004-02-11
CA2448993A1 (en) 2002-12-27
ATE291905T1 (en) 2005-04-15
DE60203501T2 (en) 2006-02-09
KR100891601B1 (en) 2009-04-08
EP1399136A2 (en) 2004-03-24
ES2238588T3 (en) 2005-09-01
WO2002102298A3 (en) 2003-11-06
WO2002102298A2 (en) 2002-12-27
CN1516578A (en) 2004-07-28
DE60203501D1 (en) 2005-05-04
JP4630545B2 (en) 2011-02-09
US20040209963A1 (en) 2004-10-21

Similar Documents

Publication Publication Date Title
US6536940B1 (en) Preparation of liquid dispersions
Gómez-Mascaraque et al. Potential of microencapsulation through emulsion-electrospraying to improve the bioaccesibility of β-carotene
Tan et al. β-Carotene nanodispersions: preparation, characterization and stability evaluation
US6406735B2 (en) Process for preparing a finely divided pulverous carotenoid retinoid or natural colourant preparation
US10004670B2 (en) Ready-to-use, stable emulsion
RU2303028C2 (en) Method for preparing lutein-containing composition, compositions and their using
de Paz et al. Development of water-soluble β-carotene formulations by high-temperature, high-pressure emulsification and antisolvent precipitation
US20010000143A1 (en) Process for the manufacture of a pulverous preparation
US20080220071A1 (en) Aqueous Suspensions of Poorly Water-Soluble and Water-Insoluble Active Ingredients and Drying Powder Produced Therefrom
WO2006032399A2 (en) Method for producing dry powders of at least one carotenoid
WO2009068432A1 (en) Pulverulent carotenoid preparation for colouring drinks
US6936279B2 (en) Microcrystalline zeaxanthin with high bioavailability in oily carrier formulations
US8137683B2 (en) Process for the preparation of dispersions
Campardelli et al. Preparation of stable aqueous nanodispersions of β-carotene by supercritical assisted injection in a liquid antisolvent
AU2002320837A1 (en) Process for the preparation of dispersions
JPH10502626A (en) Cold water dispersible composition of fat-soluble active substance
JPWO2004087645A1 (en) Method for producing carotenoid emulsion
De Paz et al. Production of water-soluble β-carotene formulations by high pressure processes
CN113841895A (en) Preparation method of beta-carotene microcapsule powder

Legal Events

Date Code Title Description
AS Assignment

Owner name: ROCHE VITAMINS INC., NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SCHAFFNER, DAVID;REEL/FRAME:015946/0483

Effective date: 20031106

AS Assignment

Owner name: DSM IP ASSETS B.V., NETHERLANDS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ROCHE VITAMINS INC.;REEL/FRAME:017671/0211

Effective date: 20060220

STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY